Integrated pharmaceutical company Dr. Reddy's Laboratories on Thursday reported an exponential rise of 672 per cent in its consolidated net profit for the first quarter of 2018-19, at Rs 456.1 crore from Rs 59.1 crore during the corresponding period of the previous fiscal.
"Profit after tax at Rs 4.6 billion. The effective tax rate is 8.9 per cent for the quarter. This is lower primarily on account of profit mix and favourable resolutions of certain tax related litigations pertaining to earlier years. The effective tax rate in Q1FY18 was 23.5 per cent," the company said in a statement.
The company's Q1 revenues were up 12 per cent to Rs 3,720.7 crore from Rs 3,315.9 crore earned during the like period of previous year.
"Improvement primarily aided by contribution from new launches including gSuboxone, leverage benefit, better product mix coupled with favorable foreign exchange," the statement added.
"This was partially offset by higher price erosions due to channel consolidation and increased competitive intensity in some of our key molecules in the US."
--IANS
rv/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
